We are live on ! Find out more
OKUR

OnKure Therapeutics
OKUR

51 hedge funds and large institutions have $114M invested in OnKure Therapeutics in 2026 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

256% more capital invested

Capital invested by funds: $32M → $114M (+$82M)

115.31% more ownership

Funds ownership: 85.96% → 201.27% (+115%)

100% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 9

16% more funds holding

Funds holding: 44 → 51 (+7)

14% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 14

Holders
51
Holders Change
+7
Holders Change %
+15.91%
% of All Funds
0.63%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.02%
New
18
Increased
12
Reduced
14
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$12.3M
2
SG
StepStone Group
California
+$6.7M
3
BI
BVF Inc
California
+$6.11M
4
VC
Vivo Capital
California
+$5.95M
5
FCMV
Foresite Capital Management VI
California
+$4.46M

Top Sellers

1
SC
Shay Capital
New York
-$2M
2
HCM
Highbridge Capital Management
New York
-$1.57M
3
CF
Cantor Fitzgerald
New York
-$1.07M
4
RA
Rosalind Advisors
Ontario, Canada
-$885K
5
Citadel Advisors
Citadel Advisors
Florida
-$573K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$16.6M +$12.3M +3,998,333 New
ACA
2
Acorn Capital Advisors
New York
$11.8M – – –
SG
3
StepStone Group
California
$11M +$6.7M +2,168,674 +441%
ACM
4
ADAR1 Capital Management
Texas
$10.1M +$4.39M +1,420,783 +140%
PM
5
Prosight Management
Texas
$8.92M +$4.13M +1,337,472 +164%
BI
6
BVF Inc
California
$8.19M +$6.11M +1,978,972 New
VC
7
Vivo Capital
California
$7.98M +$5.95M +1,927,710 New
VPC
8
Vestal Point Capital
New York
$7.62M +$3.72M +1,204,819 +190%
FCMV
9
Foresite Capital Management VI
California
$5.99M +$4.46M +1,445,783 New
Adage Capital Partners
10
Adage Capital Partners
Massachusetts
$4.99M +$3.72M +1,204,819 New
SCM
11
Sio Capital Management
New York
$4.47M +$3.33M +1,078,965 New
VCM
12
Vanguard Capital Management
Pennsylvania
$2.41M +$1.8M +582,477 New
NMC
13
NEA Management Company
Maryland
$1.98M – – –
RA
14
Rosalind Advisors
Ontario, Canada
$1.84M -$885K -286,725 -39%
Renaissance Technologies
15
Renaissance Technologies
New York
$1.56M +$401K +129,900 +53%
CG
16
Carlyle Group
District of Columbia
$1.12M – – –
AAA
17
Affinity Asset Advisors
New York
$998K +$744K +240,963 New
DT
18
DV Trading
Illinois
$998K +$744K +240,963 New
SI
19
Sofinnova Investments
California
$587K +$437K +141,700 New
SCM
20
Stonepine Capital Management
Oregon
$549K +$409K +132,578 New
SC
21
Shay Capital
New York
$547K -$2M -648,642 -83%
CF
22
Cantor Fitzgerald
New York
$414K -$1.07M -345,178 -78%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$409K +$65.7K +21,281 +27%
RC
24
Rangeley Capital
Connecticut
$393K -$154K -50,000 -34%
ACM
25
Aisling Capital Management
New York
$367K – – –
1
2 3

OKUR Hedge Fund Activity: Q1 2026 in Review

51 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q1 2026, worth a combined $114M — up 256% from $32M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new OKUR positions and 9 closed out — a net gain of 9 holders — while 12 added to existing stakes and 14 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $12.3M. The largest seller was Shay Capital, cutting an estimated $2M.

  • 51 institutional investors held OnKure Therapeutics (OKUR) as of Q1 2026, up from 44 in Q4 2025.
  • Funds reported $114M of OnKure Therapeutics stock for Q1 2026, up 256% quarter-over-quarter.
  • 18 funds opened new OnKure Therapeutics positions in Q1 2026 and 9 closed out, a net change of +9 holders.
  • The largest OnKure Therapeutics buyer in Q1 2026 was RA Capital Management, an estimated $12.3M added.
  • The largest OnKure Therapeutics seller in Q1 2026 was Shay Capital, an estimated $2M sold.

Based on aggregated 13F filings for Q1 2026.